Pharma BD Deal Intelligence
Not actually an acquisition — a 2008 Dimebon licensing deal that failed Phase 3 twice and was scrapped by 2012, with Pfizer's ~$225M upfront a total loss.
Full analysis, sources & comparables →Pfizer and Medivation announced a global agreement under which Medivation receives $225M upfront and up to $500M in development and regulatory milestones plus…
The CONCERT trial of dimebon added to donepezil also failed, ending the program; one investigator worried the negative result would make investors 'even more…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Dimebon Alzheimer's/Huntington's; $225M upfront + up to $500M milestones; failed Phase III 2010
Not actually an acquisition — a 2008 Dimebon licensing deal that failed Phase 3 twice and was scrapped by 2012, with Pfizer's ~$225M upfront a total loss.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Medivation, Inc. (this deal) | 2008 | $725M | 9 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2008 deals · Pfizer Inc. deals